Synthetic lethal screen of an EGFR-centered network to improve targeted therapies

Science Signaling

Volumn 3, Issue 140, 2010, Pages

  Astsaturov, Igor ^a   Ratushny, Vladimir ^a,b   Sukhanova, Anna ^a   Einarson, Margret B ^a   Bagnyukova, Tetyana ^a   Zhou, Yan ^a   Devarajan, Karthik ^a   Silverman, Joshua S ^a   Tikhmyanova, Nadezhda ^a,b   Skobeleva, Natalya ^a   Pecherskaya, Anna ^a   Nasto, Rochelle E ^a,c   Sharma, Catherine ^a   Jablonski, Sandra A ^d   Serebriiskii, Ilya G ^a   Weiner, Louis M ^d   Golemis, Erica A ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c DREXEL UNIVERSITY   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN KINASE C; SMALL INTERFERING RNA; STAT3 PROTEIN; AURORA KINASE; CYTOTOXIN; EGFR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CELL VIABILITY; DRUG RESISTANCE; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA INTERFERENCE; TUMOR VOLUME; DRUG ANTAGONISM; DRUG DEVELOPMENT; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION;

EUKARYOTA;

CYTOTOXINS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; NEOPLASMS; PROTEIN INTERACTION MAPPING; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77957055294     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001083     Document Type: Article

References (64)

1. W. Pao, T. Y. Wang, G. J. Riely, V. A. Miller, Q. Pan, M. Ladanyi, M. F. Zakowski, R. T. Heelan, M. G. Kris, H. E. Varmus, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
2. A. Lièvre, J. B. Bachet, D. LeCorre, V. Boige, B. Landi, J. F. Emile, J. F. Côté, G. Tomasic, C. Penna, M. Ducreux, P. Rougier, F. Penault-Llorca, P. Laurent-Puig, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
3. A. Friedman, N. Perrimon, Genetic screening for signal transduction in the era of network biology. Cell 128, 225-231 (2007).
4. A. L. Barabasi, R. Albert, Emergence of scaling in random networks. Science 286, 509-512 (1999).
5. L. H. Hartwell, J. J. Hopfield, S. Leibler, A. W. Murray, From molecular to modular cell biology. Nature 402, C47-C52 (1999).
6. V. Spirin, L. A. Mirny, Protein complexes and functional modules in molecular networks. Proc. Natl. Acad. Sci. U.S.A. 100, 12123-12128 (2003).
7. S. R. Eddy, Genetics. Total information awareness for worm genetics. Science 311, 1381-1382 (2006).
8. G. D. Bader, I. Donaldson, C. Wolting, B. F. Ouellette, T. Pawson, C. W. Hogue, BIND - The Biomolecular Interaction Network Database. Nucleic Acids Res. 29, 242-245 (2001).
9. B. Aranda, P. Achuthan, Y. Alam-Faruque, I. Armean, A. Bridge, C. Derow, M. Feuermann, A. T. Ghanbarian, S. Kerrien, J. Khadake, J. Kerssemakers, C. Leroy, M. Menden, M. Michaut, L. Montecchi-Palazzi, S. N. Neuhauser, S. Orchard, V. Perreau, B. Roechert, K. van Eijk, H. Hermjakob, The IntAct molecular interaction database in 2010. Nucleic Acids Res. 38, D525-D531 (2010).
10. T. Barrett, D. B. Troup, S. E. Wilhite, P. Ledoux, D. Rudnev, C. Evangelista, I. F. Kim, A. Soboleva, M. Tomashevsky, K. A. Marshall, K. H. Phillippy, P. M. Sherman, R. N. Muertter, R. Edgar, NCBI GEO: Archive for high-throughput functional genomic data. Nucleic Acids Res. 37, D885-D890 (2009).
11. M. Dimri, M. Naramura, L. Duan, J. Chen, C. Ortega-Cava, G. Chen, R. Goswami, N. Fernandes, Q. Gao, G. P. Dimri, V. Band, H. Band, Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res. 67, 4164-4172 (2007).
12. S. E. Seton-Rogers, Y. Lu, L. M. Hines, M. Koundinya, J. LaBaer, S. K. Muthuswamy, J. S. Brugge, Cooperation of the ErbB2 receptor and transforming growth factor β in induction of migration and invasion in mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 101, 1257-1262 (2004).
13. A. M. Jubb, S. Chalasani, G. D. Frantz, R. Smits, H. I. Grabsch, V. Kavi, N. J. Maughan, K. J. Hillan, P. Quirke, H. Koeppen, Achaete-scute like 2 (ASCL2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 25, 3445-3457 (2006).
14. L. G. van der Flier, M. E. van Gijn, P. Hatzis, P. Kujala, A. Haegebarth, D. E. Stange, H. Begthel, M. van den Born, V. Guryev, I. Oving, J. H. van Es, N. Barker, P. J. Peters, M. van de Wetering, H. Clevers, Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 136, 903-912 (2009).
15. J. Schust, B. Sperl, A. Hollis, T. U. Mayer, T. Berg, Stattic: A small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235-1242 (2006).
16. P. Dieter, E. Fitzke, RO 31-8220 and RO 31-7549 show improved selectivity for protein kinase C over staurosporine in macrophages. Biochem. Biophys. Res. Commun. 181, 396-401 (1991).
17. J. R. Grandis, S. D. Drenning, A. Chakraborty, M. Y. Zhou, Q. Zeng, A. S. Pitt, D. J. Tweardy, Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J. Clin. Invest. 102, 1385-1392 (1998).
18. L enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol. Pharmacol. 73, 1632-1642 (2008).
19. Q. W. Fan, C. Cheng, Z. A. Knight, D. Haas-Kogan, D. Stokoe, C. D. James, F. McCormick, K. M. Shokat, W. A. Weiss, EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci. Signal. 2, ra4 (2009).
20. 2-terminal kinase. J. Cell Biol. 149, 741-754 (2000).
21. S. F. Law, G. M. O'Neill, S. J. Fashena, M. B. Einarson, E. A. Golemis, The docking protein HEF1 is an apoptotic mediator at focal adhesion sites. Mol. Cell. Biol. 20, 5184-5195 (2000).
22. G. M. O'Neill, E. A. Golemis, Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics. Mol. Cell. Biol. 21, 5094-5108 (2001).
23. Y. Lu, J. Brush, T. A. Stewart, NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase/stress-activated protein kinase signaling pathway. J. Biol. Chem. 274, 10047-10052 (1999).
24. T. N. Hartmann, J. A. Burger, A. Glodek, N. Fujii, M. Burger, CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462-4471 (2005).
25. L. Song, M. Morris, T. Bagui, F. Y. Lee, R. Jove, E. B. Haura, Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66, 5542-5548 (2006).
26. E. N. Pugacheva, E. A. Golemis, The focal adhesion scaffolding protein HEF1 regulates activation of the Aurora-A and Nek2 kinases at the centrosome. Nat. Cell Biol. 7, 937-946 (2005).
27. 194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J. Biol. Chem. 280, 9013-9022 (2005).
28. X. Wang, Y. X. Zhou, W. Qiao, Y. Tominaga, M. Ouchi, T. Ouchi, C. X. Deng, Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25, 7148-7158 (2006).
29. C. Soncini, P. Carpinelli, L. Gianellini, D. Fancelli, P. Vianello, L. Rusconi, P. Storici, P. Zugnoni, E. Pesenti, V. Croci, R. Ceruti, M. L. Giorgini, P. Cappella, D. Ballinari, F. Sola, M. Varasi, R. Bravo, J. Moll, PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 12, 4080-4089 (2006).
30. P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, L. Rusconi, P. Storici, P. Zugnoni, C. Arrigoni, C. Soncini, C. Alli, V. Patton, A. Marsiglio, D. Ballinari, E. Pesenti, D. Fancelli, J. Moll, PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6, 3158-3168 (2007).
31. M. G. Manfredi, J. A. Ecsedy, K. A. Meetze, S. K. Balani, O. Burenkova, W. Chen, K. M. Galvin, K. M. Hoar, J. J. Huck, P. J. LeRoy, E. T. Ray, T. B. Sells, B. Stringer, S. G. Stroud, T. J. Vos, G. S. Weatherhead, D. R. Wysong, M. Zhang, J. B. Bolen, C. F. Claiborne, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. U.S.A. 104, 4106-4111 (2007).
32. L. W. Tari, I. D. Hoffman, D. C. Bensen, M. J. Hunter, J. Nix, K. J. Nelson, D. E. McRee, R. V. Swanson, Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorg. Med. Chem. Lett. 17, 688-691 (2007).
33. K. Fumoto, P. C. Lee, H. Saya, A. Kikuchi, AIP regulates stability of Aurora-A at early mitotic phase coordinately with GSK-3β. Regulation of mitotic progression by AIP and GSK-3. Oncogene 27, 4478-4487 (2008).
34. P. Defilippi, P. Di Stefano, S. Cabodi, p130Cas: A versatile scaffold in signaling networks. Trends Cell Biol. 16, 257-263 (2006).
35. P. A. Futreal, L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, M. R. Stratton, A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
36. E. A. Hopper-Borge, R. E. Nasto, V. Ratushny, L. M. Weiner, E. A. Golemis, I. Astsaturov, Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin. Ther. Targets 13, 339-362 (2009).
37. J. R. Pritchard, B. D. Cosgrove, M. T. Hemann, L. G. Griffith, J. R.Wands, D. A. Lauffenburger, Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol. Cancer Ther. 8, 2183-2192 (2009).
38. C. Swanton, M. Marani, O. Pardo, P. H. Warne, G. Kelly, E. Sahai, F. Elustondo, J. Chang, J. Temple, A. A. Ahmed, J. D. Brenton, J. Downward, B. Nicke, Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498-512 (2007).
39. E. Iorns, N. C. Turner, R. Elliott, N. Syed, O. Garrone, M. Gasco, A. N. Tutt, T. Crook, C. J. Lord, A. Ashworth, Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91-104 (2008).
40. A. W. Whitehurst, B. O. Bodemann, J. Cardenas, D. Ferguson, L. Girard, M. Peyton, J. D. Minna, C. Michnoff, W. Hao, M. G. Roth, X. J. Xie, M. A. White, Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446, 815-819 (2007).
41. T. T. Kwok, C. H. Mok, L. Menton-Brennan, Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res. 54, 2834-2836 (1994).
42. T. B. Brunner, K. A. Cengel, S. M. Hahn, J. Wu, D. L. Fraker, W. G. McKenna, E. J. Bernhard, Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-Ras. Cancer Res. 65, 8433-8441 (2005).
43. A. V. Sarthy, S. E. Morgan-Lappe, D. Zakula, L. Vernetti, M. Schurdak, J. C. Packer, M. G. Anderson, S. Shirasawa, T. Sasazuki, S.W. Fesik, Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol. Cancer Ther. 6, 269-276 (2007).
44. M. Kanehisa, S. Goto, S. Kawashima, A. Nakaya, The KEGG databases at GenomeNet. Nucleic Acids Res. 30, 42-46 (2002).
45. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
46. J. Schlessinger, Epidermal growth factor receptor pathway. Sci. Signal. (Connections Map in the Database of Cell Signaling, as seen January 2008), http://stke.sciencemag.org/cgi/cm/stkecm;CMP-14987.
47. K. Oda, Y. Matsuoka, A. Funahashi, H. Kitano, A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 1, 2005.0010 (2005).
48. K. Kandasamy, S. S. Mohan, R. Raju, S. Keerthikumar, G. S. Kumar, A. K. Venugopal, D. Telikicherla, J. D. Navarro, S. Mathivanan, C. Pecquet, S. K. Gollapudi, S. G. Tattikota, S. Mohan, H. Padhukasahasram, Y. Subbannayya, R. Goel, H. K. Jacob, J. Zhong, R. Sekhar, V. Nanjappa, L. Balakrishnan, R. Subbaiah, Y. L. Ramachandra, B. A. Rahiman, T. S. Prasad, J. X. Lin, J. C. Houtman, S. Desiderio, J. C. Renauld, S. N. Constantinescu, O. Ohara, T. Hirano, M. Kubo, S. Singh, P. Khatri, S. Draghici, G. D. Bader, C. Sander, W. J. Leonard, A. Pandey, NetPath: A public resource of curated signal transduction pathways. Genome Biol. 11, R3 (2010).
49. B. J. Breitkreutz, C. Stark, T. Reguly, L. Boucher, A. Breitkreutz, M. Livstone, R. Oughtred, D. H. Lackner, J. Bähler, V. Wood, K. Dolinski, M. Tyers, The BioGRID Interaction Database: 2008 update. Nucleic Acids Res. 36, D637-D640 (2008).
50. G. R. Mishra, M. Suresh, K. Kumaran, N. Kannabiran, S. Suresh, P. Bala, K. Shivakumar, N. Anuradha, R. Reddy, T. M. Raghavan, S. Menon, G. Hanumanthu, M. Gupta, S. Upendran, S. Gupta, M. Mahesh, B. Jacob, P. Mathew, P. Chatterjee, K. S. Arun, S. Sharma, K. N. Chandrika, N. Deshpande, K. Palvankar, R. Raghavnath, R. Krishnakanth, H. Karathia, B. Rekha, R. Nayak, G. Vishnupriya, H. G. Kumar, M. Nagini, G. S. Kumar, R. Jose, P. Deepthi, S. S. Mohan, T. K. Gandhi, H. C. Harsha, K. S. Deshpande, M. Sarker, T. S. Prasad, A. Pandey, Human protein reference database-2006 update. Nucleic Acids Res. 34, D411-D414 (2006).
51. P. M. Bowers, M. Pellegrini, M. J. Thompson, J. Fierro, T. O. Yeates, D. Eisenberg, Prolinks: A database of protein functional linkages derived from coevolution. Genome Biol. 5, R35 (2004).
52. I. Avila-Campillo, K. Drew, J. Lin, D. J. Reiss, R. Bonneau, BioNetBuilder: Automatic integration of biological networks. Bioinformatics 23, 392-393 (2007).
53. G. M. O'Neill, S. J. Fashena, E. A. Golemis, Integrin signaling: A new Cas(t) of characters enters the stage. Trends Cell Biol. 10, 111-119 (2000).
54. J. Yu, S. Pacifico, G. Liu, R. L. Finley Jr., DroID: The Drosophila Interactions Database, a comprehensive resource for annotated gene and protein interactions. BMC Genomics 9, 461 (2008).
55. J. H. Zhang, T. D. Chung, K. R. Oldenburg, A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4, 67-73 (1999).
56. R. C. Gentleman, V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, K. Hornik, T. Hothorn,W. Huber, S. Iacus, R. Irizarry, F. Leisch, C. Li, M. Maechler, A. J. Rossini, G. Sawitzki, C. Smith, G. Smyth, L. Tierney, J. Y. Yang, J. Zhang, Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
57. G. K. Smyth, Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
58. Y. Benjamini, Y. Hochhberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300 (1995).
59. A. I. Saeed, V. Sharov, J. White, J. Li, W. Liang, N. Bhagabati, J. Braisted, M. Klapa, T. Currier, M. Thiagarajan, A. Sturn, M. Snuffin, A. Rezantsev, D. Popov, A. Ryltsov, E. Kostukovich, I. Borisovsky, Z. Liu, A. Vinsavich, V. Trush, J. Quackenbush, TM4: A free, open-source system for microarray data management and analysis. Biotechniques 34, 374-378 (2003).
60. L. J. Jensen, M. Kuhn, M. Stark, S. Chaffron, C. Creevey, J. Muller, T. Doerks, P. Julien, A. Roth, M. Simonovic, P. Bork, C. von Mering, STRING 8 - a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 37, D412-D416 (2009).
61. Y. Assenov, F. Ramirez, S. E. Schelhorn, T. Lengauer, M. Albrecht, Computing topological parameters of biological networks. Bioinformatics 24, 282-284 (2008).
62. W. S. Rasband, ImageJ (National Institutes of Health, Bethesda, MD, 1997-2009), http://rsb.info.nih.gov/ij/.
63. T. C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
64. N. Skobeleva, S. Menon, L. Weber, E. A. Golemis, V. Khazak, In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. Mol. Cancer Ther. 6, 898-906 (2007).